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ORIGINAL RESEARCH
Objectives: The release of nitric oxide is controlled by cholinergic and adrenergic receptors.
Recent observations suggest that activation of α-adrenoceptors can inhibit the release of nitric
oxide. The aim of the present study was to examine the effect of α1- and α2-adrenoceptor
activation on nitric oxide-mediated vasodilation.
Methodology: In a first set of experiments, the endothelium-dependent vasodilators
acetylcholine (ACh), 5-hydroxytryptamine (5HT), and bradykinin (BK), and the nitric oxide
donor sodium nitroprusside (SNP) were administered in a random order in the brachial artery
together with saline, or the nonselective α-adrenoceptor agonists norepinephrine or clonidine,
or the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). The infusions
of saline, norepinephrine, clonidine, and L-NMMA started 10 minutes before the infusions of
ACh, BK, 5HT, and SNP. In a second set of experiments, cumulative doses of ACh, BK, and
5HT were infused, in a random order, intra-arterially together with saline or the selective
α1-adrenoceptor agonist methoxamine. The infusions of saline and methoxamine started
5 minutes before the infusions of ACh, BK, and 5HT. Forearm blood flow was measured
using computerized venous occlusion plethysmography.
Results: ACh, 5HT, BK, and SNP induced a significant increase in forearm blood flow (p < 0.05
for all). These vasodilator responses were significantly attenuated by norepinephrine, clonidine,
and L-NMMA (p < 0.05 for all), except for SNP. In the second set of experiments, all three
endothelium-dependent vasodilators induced a dose-dependent vasodilation, which was
significantly inhibited by methoxamine (p < 0.05).
Conclusion: These results show that endothelium-dependent nitric oxide-mediated
vasodilation is inhibited by activation of peripheral α1-adrenoceptors.
Keywords: acetylcholine, α-adrenoceptors, bradykinin, 5-hydroxytryptamine, nitric oxide,
strain-gauge plethysmography
Introduction
There is evidence to suggest that the release of vasodilator or vasoconstrictor mediators
from endothelial cells is, in part, influenced by the autonomic nervous system (Sartori
and Scherrer 1999; Zanzinger 1999). The classic example is acetylcholine (ACh),
the parasympathetic neurotransmitter, eliciting a nitric oxide-mediated vasodilation
via activation of muscarinic type-3 (M3) receptors located on the endothelial cells
(Furchgott and Zawadzki 1980; Ignarro 1989; Angus and Lew 1992; Bruning et al
1995). Besides this cholinergic receptor, it has been shown that activation of adrenergic
receptors can modulate the release of nitric oxide (Liao and Homey 1993).
Vasodilatation induced by β-adrenoceptors and α2-adrenoceptors was partially
inhibited following inhibition of nitric oxide synthase (Dawes et al 1997; Lembo et
al 1997; Majmudar et al 1999). Recently, Hijmering et al (2002) have demonstrated
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that activation of the sympathetic nervous system inhibits
flow-mediated vasodilation, suggesting inhibition of nitric
oxide by an α-adrenergic mechanism.
It was the aim of the present study to investigate the
effect of α1- and α2-adrenoceptor activation on endothelium-
dependent nitric oxide-mediated vasodilation in humans.
Materials and methods
Subjects
Twenty-three healthy non-smoking male volunteers, mean
age range 26.0 ± 2.2 years, participated in this study. All
subjects gave informed consent. The results of their medical
history, physical examination, screening laboratory tests,
and ECG were within normal ranges. All volunteers were
free from all risk factors that could be associated with
impaired endothelium function. The Leiden University
Medical Center ethics review committee approved the
protocol of the study, and the investigations complied with
the principles outlined in the Declaration of Helsinki.
Experimental procedures
The experiments were performed in a quiet room with a
constant temperature of 21–23 oC. For the duration of the
experiment, subjects were in a supine position with both
arms stabilized slightly above the level of the heart. On the
day of the study and 12 hours before, all subjects refrained
from alcohol and caffeine-containing beverages. After local
anesthesia of the skin, a 20-gauge polyethylene catheter
(Ohmeda, Swindon, UK) was inserted into the brachial
artery of the non-dominant arm for measuring intra-arterial
blood pressure and infusion of the study drugs using Harvard
volumetric precision pumps (Harvard ’22, Harvard
Apparatus Ltd, Edenbridge, Kent, UK).
The subjects rested for at least 45 minutes after the
insertion of the intra-arterial catheter to achieve a stable
baseline. Forearm blood flow was measured bilaterally,
using computerized R-wave–triggered venous occlusion
plethysmography, as described previously (Chang et al
1988). During the intra-arterial infusions, the hand was
excluded from the circulation using a small wrist cuff
inflated to 40 mmHg above the systolic blood pressure.
Between the various experiments, the wrist cuffs were
deflated and sufficient time (30–45 min) was allotted to let
forearm blood flow return to baseline levels.
Blood flow in the control arm was measured to exclude
systemic vascular effects of the drugs used. The forearm
blood flow results were not corrected by changes in forearm
blood flow in the control arm by calculating the forearm
ratio, for this would reduce the accuracy of the measure-
ments with the computerized methods used (Kamper et al
2001). Heart rate was recorded from a triple-lead
electrocardiogram.
Drugs and solutions
The following drugs were used for intra-arterial infusions:
acetylcholine￿HCl (ACh) (Bournonville Pharma BV, Den
Haag, The Netherlands), bradykinin (BK) (Clinalpha,
Darmstadt, Germany), 5-Hydroxytryptamine￿HCl (5HT)
(prepared by the Clinical Pharmacy of the Leiden University
Medical Center), sodium-nitroprusside (SNP) (prepared by
the Clinical Pharmacy of the Leiden University Medical
Center), clonidine (Boehringer Ingelheim BV, Alkmaar, The
Netherlands), methoxamine (Glaxo Smith Kline BV, Zeist,
The Netherlands), norepinephrine (prepared by the Clinical
Pharmacy of the Leiden University Medical Center), and
the competitive nitric oxide synthase inhibitor N
G-
monomethyl-L-arginine (L-NMMA) (Clinalpha, Darmstadt,
Germany). All drugs were dissolved in 0.9% NaCl except
for SNP, which was dissolved in 5% glucose. All solutions
were prepared from sterile stock solutions and ampoules
on the day of the experiments.
ACh, BK, and 5HT were used as endothelium-dependent
nitric oxide-mediated vasodilators, and SNP as an exogenous
nitric oxide donor to induce vasodilatation independent of
the endogenous nitric oxide pathway. Both norepinephrine
and clonidine were used as non-selective α1- and α2-receptor
agonists, and methoxamine as a selective α1-receptor agonist
(Bradshaw et al 1981; Jie et al 1984). L-NMMA was used
as an inhibitor of endothelium-dependent nitric oxide-
mediated vasodilatation (Angus and Lew 1992; Bruning et
al 1993; Cockcroft et al 1994).
Study protocol
To limit the length of the study day for the participant and
to preclude carry-over effects of the various study drugs
used, the study was done in two sets of experiments.
Study protocol 1
Seven subjects participated in study protocol 1. First, intra-
arterial infusions of ACh (100 ng/kg/min), BK (0.1 ng/kg/
min), 5HT (1.0 ng/kg/min), and SNP (100 ng/kg/min) were
administered in a random order together with a continuous
infusion of saline (0.4 mL/min). Then, intra-arterial infusions
of ACh, BK, 5HT, and SNP were repeated under continuousVascular Health and Risk Management 2005:1(3) 253
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intra-arterial infusion of norepinephrine (1.6 ng/kg/min) and
clonidine (60 ng/kg/min) in a random order. Finally, the
intra-arterial infusions of ACh, BK, 5HT, and SNP were
administered during simultaneous infusion of L-NMMA
(30 µg/kg/min).
Each dose of the ACh, BK, and SNP infusions was
administered for five minutes. The dose of 5HT was infused
for seven minutes. The infusions of saline, norepinephrine,
clonidine, and L-NMMA started 10 minutes before the
infusions of ACh, BK, 5HT, and SNP. Forearm blood flow,
intra-arterial blood pressure and heart rate were measured
during the two minutes immediately prior to the start of
each infusion and during the last two minutes of each
infusion.
Study protocol 2
Sixteen subjects participated in the study for protocol 2.
Six subjects received intra-arterial cumulative dose infusions
of ACh (100 and 1000 ng/kg/min); another six subjects
received intra-arterial infusions of BK (0.01 and 0.1 ng/kg/
min); and four subjects received intra-arterial infusion of
5HT (0.3 and 1.0 ng/kg/min). All these infusions were
administered under continuous infusion of saline (of 0.4 mL/
min). Subsequently, all intra-arterial infusions of ACh, BK,
and 5HT were repeated during a continuous intra-arterial
infusion of methoxamine (1 µg/kg/min).
Each dose of the ACh and BK infusions was administered
for 5 minutes. The doses of 5HT were infused for 7 minutes.
The infusions of saline, and methoxamine started 5 minutes
before the infusions of ACh, BK, and 5HT. Forearm blood
flow, intra-arterial blood pressure, and heart rate were
measured during the two minutes immediately prior to the
start of each infusion and during the last two minutes of
each dose infusion.
Analysis
Forearm blood flow is expressed as mL/min per 100 mL
forearm tissue and as percent changes from baseline.
Changes in forearm blood flow were analyzed by two-way
analysis of variance. The other results were evaluated by
Student’s t-test for paired and unpaired observations. All
p-values less than 0.05 were considered statistically
significant. All results are given as means ± standard error.
Results
During the experiments, blood flow in the control arm, heart
rate, and intra-arterial blood pressure did not show any
relevant changes (data not shown). Therefore, changes in
forearm blood flow induced by the study drugs can be
interpreted as local vascular effects of these drugs in the
forearm (Chang et al 1988; Bruning el al 1993).
Study protocol 1
The intra-arterial infusion of norepinephrine alone reduced
forearm blood flow significantly from 3.71 ± 0.28 to
2.31 ± 0.12 mL/min per 100 mL forearm tissue (p < 0.05).
Clonidine reduced the baseline forearm blood flow from
2.51 ± 0.19 to 2.03 ± 0.14 mL/min per 100 mL forearm tissue
(p < 0.05). The infusion of L-NMMA alone reduced forearm
blood flows from 2.73 ± 0.27 to 2.35 ± 0.27 mL/min per
100 mL forearm tissue (p < 0.05).
The effects of the intra-arterial infusions of the
endothelium-dependent vasodilators ACh, BK, 5HT and the
nitric oxide donor SNP on forearm blood flow are shown in
Table 1 and Figure 1. ACh 100 ng/kg/min induced a
significant increase in forearm blood flow from 3.59 ± 0.47
to 14.56 ± 4.03 mL/100 mL/min (p < 0.05). BK 0.1 ng/kg/min
and 5HT 1.0 ng/kg/min increased forearm blood flow from
Table 1 Forearm blood flows (mL/min per 100 mL forearm tissue) before and during intra-arterial infusions of acetylcholine
(100 ng/kg/min), bradykinin (0.1 ng/kg/min), 5-hydroxytryptamine (1.0 ng/kg/min), and sodium-nitroprusside (100 ng/kg/min)
Saline Norepinephrine Clonidine L-NMMA
Treatment (0.4 mL/min) (1.6 ng/kg/min) (60 ng/kg/min) (30 µg/kg/min)
Baseline 3.59 ± 0.47 2.07 ± 0.31 1.79 ± 0.14 1.89 ± 0.15
Acetylcholine 14.56 ± 4.03
a 7.00 ± 2.02
a 7.77 ± 5.52
a 2.49 ± 0.28
b
Baseline 3.40 ± 0.55 2.13 ± 0.21 1.87 ± 0.22 2.11 ± 0.20
Bradykinin 5.67 ± 0.64
a 3.18 ± 0.50
a, b 2.87 ± 0.51
a, b 2.71 ± 0.47
b
Baseline 3.60 ± 0.72 2.80 ± 0.30 2.18 ± 0.49 1.77 ± 0.08
5-Hydroxytryptamine 7.02 ± 1.11a 3.57 ± 0.41a, b 3.28 ± 0.62a, b 3.00 ± 0.70a, b
Baseline 4.11 ± 0.68 2.17 ± 0.16 1.83 ± 0.13 1.88 ± 0.15
Sodium-nitroprusside 18.89 ± 2.71a 14.52 ± 2.17a 14.46 ± 2.85a 15.63 ± 1.37a
a p < 0.05 compared with baseline.
b p < 0.05 compared with saline.
All values are means ± standard error.Vascular Health and Risk Management 2005:1(3) 254
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3.40 ± 0.55 to 5.67 ± 0.64 mL/100 mL/min and from
3.60 ± 0.72 to 7.02 ± 1.11 mL/100mL/min, respectively
(p < 0.05 for both). The infusion of SNP 100 ng/kg/min
elevated forearm blood from 4.11 ± 0.68 to 18.89 ± 2.71 mL/
100 mL/min (p < 0.05).
Concomitant infusion of norepinephrine significantly
inhibited the vasodilator responses induced by ACh with
37 ± 12%, BK with 39 ± 12%, and 5HT with 44 ± 10% when
compared with the responses under concomitant infusion
of saline (p < 0.05 for all) (see Figure 1). For concomitant
infusion of clonidine, the inhibition of Ach-, BK-, and 5HT-
mediated vasodilatation was 48 ± 18%, 45 ± 12%, and
40 ± 12%, respectively (p < 0.05 for all compared with saline)
(see Figure 1), whereas it was 65 ± 12%, 34 ± 10% and
44 ± 8% for concomitant infusion with L-NMMA (p < 0.05
for all compared with saline) (see Figure 1).
Study protocol 2
The intra-arterial infusion with methoxamine alone reduced
forearm blood significantly from 3.51 ± 0.29 to
2.03 ± 0.23 mL/min per 100 mL forearm tissue (n = 16;
p < 0.05). Table 2 shows the effects of intra-arterially infused
cumulative dose infusions of ACh, BK, and 5HT on forearm
blood flow. During the infusion of saline, all three
endothelium-dependent vasodilators induced a significant
dose-dependent increase in forearm blood flow (p < 0.05 for
all). The effects of ACh, BK, and 5HT were significantly
attenuated by the concomitant infusion of the selective
α1-receptor agonist methoxamine compared with saline
(p < 0.05), except for the highest dose of ACh used.
Table 2 Forearm blood flows (mL/min per 100 mL
forearm tissue) before and during intra-arterial infusions of
acetylcholine (100 and 1000 ng/kg/min), bradykinin (0.01 and
0.1 ng/kg/min), and 5-hydroxytryptamine (0.3 and 1.0 ng/kg/min)
Saline Methoxamine
Treatment  (0.4 mL/min)  (1 µg/kg/min)
Baseline 2.98 ± 0.38 1.65 ± 0.21b
Acetylcholine (100) 9.90 ± 2.47
a 5.15 ± 1.84
a, b
Acetylcholine (1000) 16.14 ± 3.22
a 14.77 ± 4.09
a
Baseline 3.56 ± 0.59 1.85 ± 0.47b
Bradykinin (0.01) 4.46 ± 0.87
a 1.95 ± 0.42
b
Bradykinin (0.10) 7.02 ± 1.25
a 2.51 ± 0.57
b
Baseline 4.22 ± 0.54 2.85 ± 0.46b
5-Hydroxytryptamine (0.3) 7.30 ± 1.23
a 2.54 ± 0.24
b
5-Hydroxytryptamine (1.0) 9.67 ± 1.11
a 2.81 ± 0.29
b
a p < 0.05 compared with baseline.
b p < 0.05 compared with saline.
All values are means ± standard error.
Figure 1 Forearm blood flows (mL/min per 100 mL forearm tissue) before and during intra-arterial infusions of  acetylcholine (100 ng/kg/min), bradykinin (0.1 ng/kg/
min), 5-hydroxytryptamine (1.0 ng/kg/min), and sodium-nitroprusside (100 ng/kg/min). *p < 0.05 compared with saline.
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Discussion
The main finding of this study is that activation of α1-
adrenoceptors inhibits endothelium-dependent nitric oxide-
mediated vasodilation. That the α-adrenoceptor activation
did not influence the vasodilator response induced by the
nitric oxide donor SNP indicates that α-adrenoceptor
activation attenuates the release of endogenous nitric oxide
and not the vascular response to nitric oxide per se.
It is well established that ACh, BK, and 5HT are
endothelium-dependent nitric oxide-mediated vasodilators
(Furchgott and Zawadzki 1980; Ignarro 1989; Angus and
Lew 1992; Bruning et al 1993; Cockcroft et al 1994). This
was confirmed in the present study by showing that the
vasodilator responses evoked by these vasoactive substances
were significantly attenuated by L-NMMA. The fact that
the vasodilation induced by the exogenous nitric oxide donor
SNP was not influenced by L-NMMA confirms that
L-NMMA attenuates specifically the production of
endogenous nitric oxide and not the vascular response to
nitric oxide (Jie et al 1984; Angus and Lew 1992; Bruning
et al 1993).
In the first set of experiments, we showed that the
vasodilator responses induced by ACh, BK, and 5HT were
significantly attenuated by a simultaneous infusion of the
non-selective α1- and α2-agonists norepinephrine and
clonidine, indicating α1- and/or α2-receptor activation
inhibits endothelium-dependent vasodilation. The finding
in the second set of experiments that the selective α1-receptor
agonist methoxamine also reduced the vasodilation induced
by the three different endothelium-dependent vasodilators
used provides evidence that in any case α1-adrenoceptor
activation inhibits endothelium-dependent nitric oxide-
mediated vasodilation. Based on the present findings, the
role of the α2-receptor remains unclear because we had no
selective α2-receptor agonist available for human use except
clonidine. Although clonidine has preferential affinity for
the α2-receptor, it has also affinity for the α1-adrenoceptor
(Bradshaw et al 1981).
That norepinephrine and clonidine did not influence the
vasodilator response elicited by SNP shows that reduction
of basal forearm blood flow per se (ie, vasoconstriction)
does not explain the attenuated responses of the endo-
thelium-dependent vasodilators. Although it can be argued
that the vasodilator response induced by SNP was much
greater than those induced by BK and 5HT, it was of the
same magnitude as the response induced by ACh.
Furthermore, since SNP is an exogenous donor of nitric
oxide, it provides evidence that α-adrenoceptor activation
does not inhibit the vasodilator response induced by nitric
oxide.
These findings corroborate the results of the recent
experiments of Hijmering et al (2002) showing that
sympathetic activation inhibits flow-mediated vasodilation
in the human forearm. Flow-mediated vasodilation is
mediated via shear stress, inducing the release of nitric oxide
(Koller et al 1994; Davies et al 1997). It is often argued that
shear stress-induced release of nitric oxide is under the
control of different mechanisms than agonist- or
microvascular-mediated nitric oxide release. This is based
on the observations that adrenoceptor activation does not
influence ACh- and metacholine-induced vasodilation
(Rector et al 1993; Engelke et al 1997). However, in these
experiments, relatively high doses of ACh and metacholine
were used, and it has been shown that ACh and its synthetic
equivalent, metacholine, induce a nitric oxide-independent
vasodilation in the higher dose range (Bruning et al 1996;
Kamper et al 2002). This is in accordance with the present
finding that, in contrast with the lower dose of ACh used,
the vasodilator response induced by the highest dose of ACh
was not influenced by the selective α1-receptor agonist,
methoxamine. However, when Engelke et al (1997) used a
lower dose of ACh comparable to our dose of 100 ng/kg/
min, the responses to lower body suction and phentolamine
were significantly attenuated, corroborating our results.
From the present findings and the literature, evidence
emerges that the endocrine function of the endothelial cells
is controlled, in part, by the autonomic nervous system (Toda
and Okamura 2003). Stimulation of the cholinergic M3-
receptors and β2-adrenoceptors induce the release of nitric
oxide (Bruning et al 1995; Dawes et al 1997; Majmudar et
al 1999); whereas, as shown in the present study, activation
of α1-adrenoceptors attenuates the release of nitric oxide.
The α2-receptors seem to have a dual effect on nitric oxide
release, whereby the inhibitory effects seem to be most
prominent in the human forearm vascular bed (Jie et al
1984). These findings might be an explanation for the better
survival of heart failure patients treated with the non-
selective β-blocker carvedilol, which has α1-receptor
blocking properties, compared with patients treated with
the selective β1-blocker metoprolol (Poole-Wilson et al
2003). Heart failure is associated with sympathetic activation
and endothelial dysfunction (Cohn et al 1984; Ferguson et
al 1990).  It could be hypothesized that the additional α1-
receptor-blocking properties of carvedilol might lead to
improved endothelial mediated, nitric oxide-induced
vasodilation in these patients; thus further resulting in aVascular Health and Risk Management 2005:1(3) 256
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reduction in peripheral vascular resistance and reducing
impedance to flow, and hence lowering the work-load
placed on the myocardium, which is always beneficial in a
patient with a failing heart. This, however, needs to be further
investigated.
Limitations of the present study
The conclusion of the present study – that in humans,
endothelium-dependent nitric oxide-mediated vasodilation
is attenuated by activation of peripheral α1-adrenoceptors –
is based on the lack of change to SNP-mediated blood flow.
There exists an indirect measurement of nitric oxide by
changes in nitrite/nitrate levels (Kawano et al 1999). This
measurement was not performed in this study. Another
explanation of a reduced nitric oxide-mediated vasodilation
is that the bioavailability of the endothelium-generated nitric
oxide is reduced due to impaired NADPH-oxidase activity
(De Vriese et al 2000).
From the present findings, we conclude that in humans,
endothelium-dependent nitric oxide-mediated vasodilation
is attenuated by activation of peripheral α1-adrenoceptors.
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